1
|
Fagerstrom JM. Radiation oncology department policy development for patients who may become pregnant. J Appl Clin Med Phys 2024; 25:e14256. [PMID: 38175957 PMCID: PMC10860450 DOI: 10.1002/acm2.14256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 12/07/2023] [Accepted: 12/19/2023] [Indexed: 01/06/2024] Open
Abstract
In the context of radiation oncology, radiation exposure from radiation therapy simulation, image guidance, and radiation therapy procedures can have severe adverse biological effects on a developing embryo or fetus. Patients who may be pregnant are screened for the possibility of pregnancy to prevent unnecessary or excessive exposure of radiation in utero. Some radiation therapy patients for whom a pregnancy test is indicated may elect to decline the test. In addition, some patients who are found upon screening to be pregnant may decide, with their attending radiation oncologist, to continue with treatment. A radiation oncology department policy was developed to provide guidelines regarding screening and consent. The policy was designed to prevent unnecessary exposure to patients who may be pregnant, and to limit dose to the embryo or fetus in patients for whom treatment is medically indicated. The policy is presented as an example for physicists intending to develop or revise their own practice's policy regarding patients who may become pregnant.
Collapse
Affiliation(s)
- Jessica M. Fagerstrom
- Department of Radiation OncologyUniversity of WashingtonSeattleWashingtonUSA
- Department of Radiation OncologyKaiser PermanenteSeattleWashingtonUSA
| |
Collapse
|
2
|
Sorouri K, Loren AW, Amant F, Partridge AH. Patient-Centered Care in the Management of Cancer During Pregnancy. Am Soc Clin Oncol Educ Book 2023; 43:e100037. [PMID: 37220323 DOI: 10.1200/edbk_100037] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The management of cancer during pregnancy requires a patient-centered, multidisciplinary approach to balance maternal and fetal well-being given the rarity of this clinical scenario and lack of substantial data. Involvement of oncology and nononcology medical specialists and ethical, legal, and psychosocial supports, as needed, is instrumental in navigating the complexities of care for this patient population. Critical periods of fetal development and physiological changes in pregnancy must be considered when planning diagnostic and therapeutic approaches during pregnancy. The complexity of symptom recognition and interventional approaches contributes to diagnostic delays of cancers during pregnancy. Ultrasound and whole-body diffusion-weighted magnetic resonance imaging are safe throughout pregnancy. Surgery can be safely performed throughout pregnancy, with the early second trimester preferred for intra-abdominal surgery. Chemotherapy can be safely administered after 12-14 weeks of gestation until 1-3 weeks before the anticipated delivery. Most targeted and immunotherapeutic agents are contraindicated during pregnancy because of limited data. Pelvic radiation during pregnancy is absolutely contraindicated, while if radiation to the upper body is needed, administration should only be considered early in pregnancy. To ensure that the total cumulative fetal exposure to ionizing radiation does not exceed 100 mGy, early inclusion of the radiology team in the care plan is required. Closer prenatal monitoring is recommended for maternal and fetal treatment-related toxicities. Delivery before 37 weeks of gestation should be avoided if possible, and vaginal delivery is preferred unless obstetrically indicated or specific clinical scenarios. Postpartum, breastfeeding should be discussed, and the neonate should receive blood work to assess for acute toxicities with follow-up arranged for long-term monitoring.
Collapse
Affiliation(s)
- Kimia Sorouri
- Dana-Farber Cancer Institute, Boston, MA
- Harvard Medical School, Boston, MA
| | - Alison W Loren
- Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA
| | - Frédéric Amant
- Netherlands Cancer Institute, Amsterdam, the Netherlands
- KU Leuven, Leuven, Belgium
- University of Amsterdam, Amsterdam, the Netherlands
| | - Ann H Partridge
- Dana-Farber Cancer Institute, Boston, MA
- Harvard Medical School, Boston, MA
| |
Collapse
|
3
|
Wong YM, Koh CWY, Lew KS, Chua CGA, Nei W, Tan HQ, Lee JCL, Mazonakis M, Damilakis J. A review on fetal dose in Radiotherapy: A historical to contemporary perspective. Phys Med 2023; 105:102513. [PMID: 36565555 DOI: 10.1016/j.ejmp.2022.102513] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Revised: 11/09/2022] [Accepted: 12/16/2022] [Indexed: 12/24/2022] Open
Abstract
This paper aims to review on fetal dose in radiotherapy and extends and updates on a previous work1 to include proton therapy. Out-of-field doses, which are the doses received by regions outside of the treatment field, are unavoidable regardless of the treatment modalities used during radiotherapy. In the case of pregnant patients, fetal dose is a major concern as it has long been recognized that fetuses exposed to radiation have a higher probability of suffering from adverse effects such as anatomical malformations and even fetal death, especially when the 0.1Gy threshold is exceeded. In spite of the low occurrence of cancer during pregnancy, the radiotherapy team should be equipped with the necessary knowledge to deal with fetal dose. This is crucial so as to ensure that the fetus is adequately protected while not compromising the patient treatment outcomes. In this review paper, various aspects of fetal dose will be discussed ranging from biological, clinical to the physics aspects. Other than fetal dose resulting from conventional photon therapy, this paper will also extend the discussion to modern treatment modalities and techniques, namely proton therapy and image-guided radiotherapy, all of which have seen a significant increase in use in current radiotherapy. This review is expected to provide readers with a comprehensive understanding of fetal dose in radiotherapy, and to be fully aware of the steps to be taken in providing radiotherapy for pregnant patients.
Collapse
Affiliation(s)
- Yun Ming Wong
- Division of Physics and Applied Physics, Nanyang Technological University, Singapore
| | | | - Kah Seng Lew
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore
| | | | - Wenlong Nei
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore
| | - Hong Qi Tan
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
| | - James Cheow Lei Lee
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore; Division of Physics and Applied Physics, Nanyang Technological University, Singapore
| | - Michael Mazonakis
- Department of Medical Physics, School of Medicine, University of Crete, Greece
| | - John Damilakis
- Department of Medical Physics, School of Medicine, University of Crete, Greece
| |
Collapse
|
4
|
Development of a computational pregnant female phantom and calculation of fetal dose during a photon breast radiotherapy. Radiol Oncol 2022; 56:541-551. [PMID: 36259318 PMCID: PMC9784366 DOI: 10.2478/raon-2022-0039] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Accepted: 08/01/2022] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND The incidence of carcinoma during pregnancy is reported to be 1:1000-1:1500 pregnancies with the breast carcinoma being the most commonly diagnosed. Since the fetus is most sensitive to ionizing radiation during the first two trimesters, there are mixed clinical opinions and no uniform guidelines on the use of radiotherapy during pregnancy. Within this study the pregnant female phantom in the second trimester, that can be used for radiotherapy treatment planning (as DICOM data), Monte Carlo simulations (as voxelized geometry) and experimental dosimetry utilizing 3D printing of the molds (as .STL files), was developed. MATERIALS AND METHODS The developed phantom is based on MRI images of a female patient in her 18th week of pregnancy and CT images after childbirth. Phantom was developed in such a manner that a pregnant female was scanned "in vivo" using MRI during pregnancy and CT after childbirth. For the treatment of left breast carcinoma, 3D conformal radiotherapy was used. The voxelized geometry of the phantom was used for Monte Carlo (MC) simulations using Monte Carlo N-Particle transport codeTM 6.2 (MCNP). CONCLUSIONS The modeled photon breast radiotherapy plan, applied to the phantom, indicated that the fetus dose is 59 mGy for 50 Gy prescribed to the breast. The results clearly indicate that only 9.5% of the fetal dose is caused by photons that are generated in the accelerator head through scattering and leakage, but the dominant component is scattered radiation from the patient's body.
Collapse
|
5
|
Makkia RS, Nelson KH, Zaidi H, Dingfelder M. Hybrid computational pregnant female phantom construction for radiation dosimetry applications. Biomed Phys Eng Express 2022; 8. [PMID: 36137492 DOI: 10.1088/2057-1976/ac9414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 09/22/2022] [Indexed: 11/12/2022]
Abstract
The number of patients undergoing diagnostic radiology and radiation therapy procedures has increased drastically owing to improvements in cancer diagnosis and treatment and, consequently, patient survival. However, the risk of the occurrence of secondary malignancies due to radiation exposure remains a matter of concern. There are concerns about the fetus's health when pregnant women are exposed to and/or treated with ionizing radiation at various stages of pregnancy. We previously published three hybrid computational fetus phantoms, which contained 27 fetal organs, as a beginning point for developing the whole hybrid computational pregnant phantom set, which is the second objective of this study. An ICRP reference female voxel model was converted to a non-uniform rational basis spline (NURBS) surface model in order to construct a hybrid computational female phantom as a pregnant mother to each fetus model. Both the fetal and maternal organs were matched with ICRP-89 reference data. In order to create a complete standard pregnant computational phantom set at 20, 30, and 35 weeks of pregnancy, the model mother's reproductive organs were removed, and the fetus phantoms with appropriate placental and uterine models were added female pelvis using a 3D-modeling software. With the aid of radiological image sets that had been initially used to construct the fetus models, each fetus' position and rotation inside the uterus were carefully adjusted to represent the real fetal locations inside the uterus. The resulting fetus phantom was positioned in the appropriate location, matching the original radiological image sets. An obstetrician-gynecologist reviewed the complete internal anatomy of all fetus phantoms and the pregnant female for accuracy, and suggested changes were implemented as needed. This new set of hybrid computational pregnant phantom models has realistic anatomical details that can help evaluate fetal radiation doses where realistic fetal computational human phantoms are needed.
Collapse
Affiliation(s)
- Rasha S Makkia
- Department of Radiology and Biomedical Imaging, School of Medicine , Yale University School of Medicine Department of Radiology and Biomedical Imaging, 789 Howard Avenue, New Haven, Connecticut, 06520-8042, UNITED STATES
| | - Keith H Nelson
- Department of Obstetrics and Gynecology, Brody School of Medicine, East Carolina University, East Carolina University, Room 164 Medical Annex - Vidant Medical Center Greenville, NC 27834, Greenville, North Carolina, 27834, UNITED STATES
| | - Habib Zaidi
- Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, University Hospital of Geneva, 24 Rue Micheli-du-Crest, CH-1211, 4 Geneva Neuroscience Center, Geneva University, Geneva, Switzerland, Geneva, 1205 , SWITZERLAND
| | - Michael Dingfelder
- East Carolina University Department of Physics C-209 Howell Science Complex , Mailstop 563 , 1000 E. 5th Street, East Carolina University, Austin 127, Mailstop 563, Greenville, North Carolina, 27858, UNITED STATES
| |
Collapse
|
6
|
Brower CH, Baugh CW, Shokoohi H, Liteplo AS, Duggan N, Havens J, Askari R, Rehani MM, Kapur T, Goldsmith AJ. Point-of-care ultrasound-first for the evaluation of small bowel obstruction: National cost savings, length of stay reduction, and preventable radiation exposure. Acad Emerg Med 2022; 29:824-834. [PMID: 35184354 DOI: 10.1111/acem.14464] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 01/31/2022] [Accepted: 02/16/2022] [Indexed: 11/29/2022]
Abstract
OBJECTIVES Computed tomography (CT) has long been the gold standard in diagnosing patients with suspected small bowel obstruction (SBO). Recently, point-of-care ultrasound (POCUS) has demonstrated comparable test characteristics to CT imaging for the diagnosis of SBO. Our primary objective was to estimate the annual national cost saving impact of a POCUS-first approach for the evaluation of SBO. Our secondary objectives were to estimate the reduction in radiation exposure and emergency department (ED) length of stay (LOS). METHODS We created and ran 1000 trials of a Monte Carlo simulation. The study population included all patients presenting to the ED with abdominal pain who were diagnosed with SBO. Using this simulation, we modeled the national annual cost savings in averted advanced imaging from a POCUS-first approach for SBO. The model assumes that all patients who require surgery or have non-diagnostic POCUS exams undergo CT imaging. The model also conservatively assumes that a subset of patients with diagnostic POCUS exams undergo additional confirmatory CT imaging. We used the same Monte Carlo model to estimate the reduction in radiation exposure and total ED bed hours saved. RESULTS A POCUS-first approach for diagnosing SBO was estimated to save a mean (±SD) of $30.1 million (±8.9 million) by avoiding 143,000 (±31,000) CT scans. This resulted in a national cumulative decrease of 507,000 bed hours (±268,000) in ED LOS. The reduction in radiation exposure to patients could potentially prevent 195 (±56) excess annual cancer cases and 98 (±28) excess annual cancer deaths. CONCLUSIONS If adopted widely and used consistently, a POCUS-first algorithm for SBO could yield substantial national cost savings by averting advanced imaging, decreasing ED LOS, and reducing unnecessary radiation exposure in patients. Clinical decision tools are needed to better identify which patients would most benefit from CT imaging for SBO in the ED.
Collapse
Affiliation(s)
- Charles H. Brower
- Department of Emergency Medicine University of Cincinnati Medical Center Cincinnati Ohio USA
| | - Christopher W. Baugh
- Department of Emergency Medicine, Harvard Medical School Brigham and Women's Hospital Boston Massachusetts United States
| | - Hamid Shokoohi
- Department of Emergency Medicine, Harvard Medical School Massachusetts General Hospital Boston Massachusetts USA
| | - Andrew S. Liteplo
- Department of Emergency Medicine, Harvard Medical School Massachusetts General Hospital Boston Massachusetts USA
| | - Nicole Duggan
- Department of Emergency Medicine, Harvard Medical School Brigham and Women's Hospital Boston Massachusetts United States
| | - Joaquim Havens
- Department of Surgery, Division of Trauma, Burn, and Surgical Critical Care, Harvard Medical School Brigham and Women's Hospital Boston Massachusetts USA
| | - Reza Askari
- Department of Surgery, Division of Trauma, Burn, and Surgical Critical Care, Harvard Medical School Brigham and Women's Hospital Boston Massachusetts USA
| | - Madan M. Rehani
- Department of Radiology Massachusetts General Hospital Boston Massachusetts USA
| | - Tina Kapur
- Department of Radiology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA
| | - Andrew J. Goldsmith
- Department of Emergency Medicine, Harvard Medical School Brigham and Women's Hospital Boston Massachusetts United States
| |
Collapse
|
7
|
Tillery H, Moore M, Gallagher KJ, Taddei PJ, Leuro E, Argento DC, Moffitt GB, Kranz M, Carey M, Heymsfield S, Newhauser WD. Personalized 3D-printed anthropomorphic whole-body phantom irradiated by protons, photons, and neutrons. Biomed Phys Eng Express 2022; 8. [PMID: 35045408 DOI: 10.1088/2057-1976/ac4d04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2021] [Accepted: 01/19/2022] [Indexed: 11/12/2022]
Abstract
The objective of this study was to confirm the feasibility of three-dimensionally-printed (3D-printed), personalized whole-body anthropomorphic phantoms for radiation dose measurements in a variety of charged and uncharged particle radiation fields. We 3D-printed a personalized whole-body phantom of an adult female with a height of 154.8 cm, mass of 90.7 kg, and body mass index of 37.8 kg/m2. The phantom comprised of a hollow plastic shell filled with water and included a watertight access conduit for positioning dosimeters. It is compatible with a wide variety of radiation dosimeters, including ionization chambers that are suitable for uncharged and charged particles. Its mass was 6.8 kg empty and 98 kg when filled with water. Watertightness and mechanical robustness were confirmed after multiple experiments and transportations between institutions. The phantom was irradiated to the cranium with therapeutic beams of 170-MeV protons, 6-MV photons, and fast neutrons. Radiation absorbed dose was measured from the cranium to the pelvis along the longitudinal central axis of the phantom. The dose measurements were made using established dosimetry protocols and well-characterized instruments. For the therapeutic environments considered in this study, stray radiation from intracranial treatment beams was the lowest for proton therapy, intermediate for photon therapy, and highest for neutron therapy. An illustrative example set of measurements at the location of the thyroid for a square field of 5.3 cm per side resulted in 0.09, 0.59, and 1.93 cGy/Gy from proton, photon, and neutron beams, respectively. In this study, we found that 3D-printed personalized phantoms are feasible, inherently reproducible, and well-suited for therapeutic radiation measurements. The measurement methodologies we developed enabled the direct comparison of radiation exposures from neutron, proton, and photon beam irradiations.
Collapse
Affiliation(s)
- Hunter Tillery
- Radiation Medicine, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, KPV4, Portland, Oregon, 97239-3098, UNITED STATES
| | - Meagan Moore
- Louisiana State University, 439-B Nicholson Hall, Tower Dr., Baton Rouge, Louisiana, 70803-4001, UNITED STATES
| | - Kyle Joseph Gallagher
- Radiation Medicine, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, KPV4, Portland, Oregon, 97239-3098, UNITED STATES
| | - Phillip J Taddei
- Department of Radiation Oncology, Mayo Clinic, 200 First St. SW, Rochester, Minnesota, 55905, UNITED STATES
| | - Eric Leuro
- Seattle Cancer Care Alliance, 1570 N 115th St, Seattle, Washington, 98133, UNITED STATES
| | - David C Argento
- Radiation Oncology, University of Washington School of Medicine, 1959 NE Pacific St, Seattle, Washington, 98195, UNITED STATES
| | - Gregory B Moffitt
- Radiation Oncology, University of Washington School of Medicine, 1959 NE Pacific St, Seattle, Washington, 98195, UNITED STATES
| | - Marissa Kranz
- University of Washington School of Medicine, 1959 NE Pacific St, Seattle, Washington, 98195, UNITED STATES
| | - Margaret Carey
- Louisiana State University, 439-B Nicholson Hall, Tower Dr., Baton Rouge, Louisiana, 70803-4001, UNITED STATES
| | - Steven Heymsfield
- Louisiana State University, 439-B Nicholson Hall, Tower Dr., Baton Rouge, Louisiana, 70803-4001, UNITED STATES
| | - Wayne David Newhauser
- Louisiana State University, 439-B Nicholson Hall, Tower Dr., Baton Rouge, Louisiana, 70803-4001, UNITED STATES
| |
Collapse
|
8
|
Assessment of Fetal Dose and Health Effect to the Fetus from Breast Cancer Radiotherapy during Pregnancy. Life (Basel) 2022; 12:life12010084. [PMID: 35054476 PMCID: PMC8780279 DOI: 10.3390/life12010084] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2021] [Revised: 12/30/2021] [Accepted: 01/05/2022] [Indexed: 01/26/2023] Open
Abstract
Decision for radiotherapy during the first trimester of pregnancy may occur, as patients may not realize their pregnancy at the very early stage. Since radiation dose can affect fetal development, the aim of this study was to evaluate fetal dose and associated deterministic effects and risks to the fetus from breast cancer radiotherapy of an 8-week pregnant patient. PHITS (Particle and Heavy Ion Transport code System) Monte Carlo simulation and the J-45 computational pregnancy phantom were used to simulate breast cancer radiotherapy from a 6 MV TrueBeam linear accelerator using the three dimensional-conformal radiotherapy (3D-CRT) technique with a prescribed dose to the planning target volume (PTV) of 50 Gy. Once the fetal dose was evaluated, the occurrence of the deterministic effects and risks for developing stochastic effects in the fetus were assessed using the recommendations of NCRP Report No. 174, AAPM Report No. 50, and ICRP Publication 84. The fetal dose was evaluated to be 3.37 ± 2.66 mGy, suggesting that the fetus was expected to have no additional deterministic effects, while the risks for developing cancer and malfunctions were similar to that expected from exposure to background radiation. The comparison with the other studies showed that accurate consideration of fetal position and size was important for dose determination in the fetus, especially at the early pregnancy stage when the fetus is very small.
Collapse
|
9
|
Catusso L, Santos WS, da Silva RMV, Valença JVB. Mobile shielding evaluation on the fetal dose during a breast radiotherapy using Monte Carlo simulation. Phys Med 2021; 84:24-32. [PMID: 33826997 DOI: 10.1016/j.ejmp.2021.03.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 03/10/2021] [Accepted: 03/20/2021] [Indexed: 11/15/2022] Open
Abstract
PURPOSE Evaluation of the out-of-field dose is an important aspect in radiotherapy. Due to the fetus radiosensitivity, this evaluation becomes even more conclusive when the patient is pregnant. In this work, a linear accelerator Varian Clinac 2100c operating at 6 MV, a pregnant anthropomorphic phantom (Maria), and different shields added above the abdominal region of the phantom were used for the analysis based on MCNPX. METHODS The simulations were performed for the medial and lateral projections, using either an open field collimation (10×16cm2) or a multileaf collimator. The added shields (M1 and M2) were designed based on models proposed by Stovall et al. [1], intending to reduce the deposited dose on the fetus and related structures. RESULTS The presence of the shields showed to be effective in reducing the doses on the fetus, amniotic sac, and placenta, for example. A reduction of about 43% was found in the dose on the fetus when M2 was added, using the open field collimation, in comparison with the situation with no shield, being the lateral projection the main responsible for the dose. The use of MLC significatively reduced the doses in different structures, including on the fetus and amniotic sac, for example, in comparison to the open field situation. A slight increment on the dose in organs such as the eyes, thyroid and brain was found in both collimation systems, due to the presence of the shields. The contribution of the leakage radiation from the tube head of the linear accelerator was found to be in the order of µGy, being reduced by the presence of the M2 shield. CONCLUSION Using the shields showed to be an essential feature in order to reduce the dose not only on the fetus, but also in important structures responsible to its development.
Collapse
Affiliation(s)
- Leonardo Catusso
- Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil.
| | - William S Santos
- Federal University of Uberlândia (INFIS/UFU), Uberlândia, MG, Brazil
| | | | - João V B Valença
- Federal University of Health Sciences of Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil
| |
Collapse
|
10
|
Phantom dosimetry and cancer risks estimation undergoing 6 MV photon beam by an Elekta SL-25 linac. Appl Radiat Isot 2020; 163:109232. [PMID: 32561064 DOI: 10.1016/j.apradiso.2020.109232] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 04/25/2020] [Accepted: 05/17/2020] [Indexed: 01/15/2023]
Abstract
The High-energy linear accelerator (linac) is a valuable tool and the most commonly used devices for external beam radiation treatments in subjects suffer from cancer. To estimate the dose deposited in several organs of a female patient due to pelvic irradiation by an Elekta SL-25 linac in 6 MV photon beam mode, the MCNPX code is used considering the most details of linac. The equivalent dose in different organs is computed according to the face down position (prone) of MIRD and UFRO phantoms. The data obtained using MCNPX show that the received dose in all commons organs of MIRD and UFRO phantoms is 535.73 and 433.09 mSv/Gyx, respectively. The risks of second cancer incidence and mortality during radiotherapy treatment are compared between MIRD and UFRO phantoms. The results indicated that bladder has the maximum risk of secondary cancer incidence risk of 142.85 and 135.34 per 105 persons based on MIRD and UFRO phantoms, respectively; while the total risk is about 1 in 163 and about 1 in 101 in these phantoms.
Collapse
|
11
|
Monte Carlo simulation of non-target organ doses and radiation-induced secondary cancer risk in Tanzania from radiotherapy of nasopharyngeal by using Co-60 source. Radiat Phys Chem Oxf Engl 1993 2020. [DOI: 10.1016/j.radphyschem.2020.108731] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
12
|
Miften M, Mihailidis D, Kry SF, Reft C, Esquivel C, Farr J, Followill D, Hurkmans C, Liu A, Gayou O, Gossman M, Mahesh M, Popple R, Prisciandaro J, Wilkinson J. Management of radiotherapy patients with implanted cardiac pacemakers and defibrillators: A Report of the AAPM TG-203 †. Med Phys 2019; 46:e757-e788. [PMID: 31571229 DOI: 10.1002/mp.13838] [Citation(s) in RCA: 73] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 07/16/2019] [Accepted: 08/28/2019] [Indexed: 11/11/2022] Open
Abstract
Managing radiotherapy patients with implanted cardiac devices (implantable cardiac pacemakers and implantable cardioverter-defibrillators) has been a great practical and procedural challenge in radiation oncology practice. Since the publication of the AAPM TG-34 in 1994, large bodies of literature and case reports have been published about different kinds of radiation effects on modern technology implantable cardiac devices and patient management before, during, and after radiotherapy. This task group report provides the framework that analyzes the potential failure modes of these devices and lays out the methodology for patient management in a comprehensive and concise way, in every step of the entire radiotherapy process.
Collapse
Affiliation(s)
- Moyed Miften
- Task Group 203, Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, 80045, USA
| | - Dimitris Mihailidis
- Task Group 203, University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, PA, 19104, USA
| | - Stephen F Kry
- Department of Radiation Physics, UT MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - Chester Reft
- Department of Radiation Oncology, University of Chicago, Chicago, IL, 60637, USA
| | - Carlos Esquivel
- Department of Radiation Oncology, UT Health Sciences Center, San Antonio, TX, 78229, USA
| | - Jonathan Farr
- Division of Radiological Sciences, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - David Followill
- Department of Radiation Physics, UT MD Anderson Cancer Center, Houston, TX, 77030, USA
| | - Coen Hurkmans
- Department of Radiotherapy, Catharina Hospital, Eindhoven, the Netherlands
| | - Arthur Liu
- Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO, 80045, USA
| | - Olivier Gayou
- Department of Radiation Oncology, Allegheny General Hospital, Pittsburg, PA, 15212, USA
| | - Michael Gossman
- Department of Radiation Oncology, Tri-State Regional Cancer Center, Ashland, KY, 41101, USA
| | - Mahadevappa Mahesh
- Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA
| | - Richard Popple
- Department of Radiation Oncology, University of Alabama, Birmingham, AL, 35249, USA
| | - Joann Prisciandaro
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA
| | | |
Collapse
|
13
|
Yamada K, Chigusa Y, Nomura M, Sakanaka K, Nakamura M, Yano S, Tsunoda S, Kondoh E, Mandai M. A Case of Recurrent Esophageal Cancer Treated with Concurrent Chemoradiation Therapy in Pregnancy. Case Rep Obstet Gynecol 2018; 2018:1280582. [PMID: 30627462 PMCID: PMC6304601 DOI: 10.1155/2018/1280582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Revised: 11/14/2018] [Accepted: 11/22/2018] [Indexed: 12/02/2022] Open
Abstract
Esophageal cancer rarely coincides with pregnancy, and only five cases have been reported thus far. The management of esophageal cancer during pregnancy is extremely challenging due to its aggressive nature. We herein report a case of recurrent esophageal cancer in pregnancy. A 41-year-old multigravida with a history of esophageal squamous cell cancer treated with esophagectomy and perioperative chemotherapy was diagnosed with local recurrent carcinoma of the residual esophagus at 16 weeks of gestation. The patient strongly desired to continue the pregnancy, and concurrent chemoradiation therapy (CRT) consisting of 50.4 Gy of radiation, cisplatin, and 5-fluorouracil was carried out from 19 weeks of gestation. CRT was dramatically effective, and the recurrent lesion disappeared. At 38 weeks of gestation, she underwent cesarean section and delivered a healthy female baby. Both maternal and fetal courses were satisfactory, and the patient has been free of disease for 12 months. This is the first case of recurrent esophageal cancer in pregnancy in which CRT was completed without reducing treatment intensity and led to a complete response. Nevertheless, little is known regarding the safety and possible adverse effects of CRT on the fetus. Therefore, deliberate selection of patients and long-term follow-up of the child are necessary.
Collapse
Affiliation(s)
- Kaori Yamada
- Department of Gynecology and Obstetrics, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Yoshitsugu Chigusa
- Department of Gynecology and Obstetrics, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Motoo Nomura
- Department of Therapeutic Oncology, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Katsuyuki Sakanaka
- Department of Radiation Oncology and Image-Applied Therapy, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Mitsuhiro Nakamura
- Department of Radiation Oncology and Image-Applied Therapy, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
- Division of Medical Physics, Department of Information Technology and Medical Engineering, Human Health Sciences, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Shinsuke Yano
- Division of Clinical Radiology Service, Kyoto University Hospital, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Shigeru Tsunoda
- Department of Surgery, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Eiji Kondoh
- Department of Gynecology and Obstetrics, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| | - Masaki Mandai
- Department of Gynecology and Obstetrics, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
| |
Collapse
|
14
|
Kuzmin GA, Mille MM, Jung JW, Lee C, Pelletier C, Akabani G, Lee C. A Novel Method to Extend a Partial-Body CT for the Reconstruction of Dose to Organs beyond the Scan Range. Radiat Res 2018; 189:618-626. [PMID: 29617205 DOI: 10.1667/rr14999.1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Epidemiological investigation is an important approach to assessing the risk of late effects after radiotherapy, and organ dosimetry is a crucial part of such analysis. Computed tomography (CT) images, if available, can be a valuable resource for individualizing the dosimetry, because they describe the specific anatomy of the patient. However, CT images acquired for radiation treatment planning purposes cover only a portion of the body near the target volume, whereas for epidemiology, the interest lies in the more distant normal tissues, which may be located outside the scan range. To address this challenge, we developed a novel method, called the Anatomically Predictive Extension (APE), to extend a partial-body CT image stack using images of a computational human phantom matched to the patient based on their height and weight. To test our method, we created five APE phantoms from chest and abdominal images extracted from the chest-abdomen-pelvis (CAP) CT scans of five patients. Organ doses were calculated for simple chest and prostate irradiations that were planned on the reference computational phantom (assumed patient geometry if no CT images are available), APE phantoms (patient-phantom hybrid given a partial-body patient CT) and full patient CAP CT scans (ground truth). The APE phantoms and patient CAP CT scans resulted in nearly identical dosimetry for those organs that were fully included in the partial-body CT used to construct the APE. The calculated doses to these same organs in the reference phantoms differed by up to 20% and 52% for the chest and prostate cases, respectively. For organs outside the scan coverage, the reference phantom showed, on average, dose differences of 31% (chest case) and 41% (prostate case). For the APE phantoms, these values were 26% (chest) and 17% (prostate). The APE method combines patient and phantom images to improve organ dosimetry both inside and outside the scan range. We intend to use the APE method for estimating dose for organs peripheral to the treatment fields; however, this method is quite generalizable with many potential applications.
Collapse
Affiliation(s)
- Gleb A Kuzmin
- a Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850.,d Department of Nuclear Engineering, Texas A&M University, College Station, Texas 77843
| | - Matthew M Mille
- a Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850
| | - Jae Won Jung
- b Department of Physics, East Carolina University, Greenville, North Carolina 27858
| | - Choonik Lee
- c Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109
| | | | - Gamal Akabani
- d Department of Nuclear Engineering, Texas A&M University, College Station, Texas 77843
| | - Choonsik Lee
- a Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850
| |
Collapse
|
15
|
Leonardi M, Cecconi A, Luraschi R, Rondi E, Cattani F, Lazzari R, Morra A, Soto S, Zanagnolo V, Galimberti V, Gentilini O, Peccatori F, Jereczek-Fossa B, Orecchia R. Electron Beam Intraoperative Radiotherapy (ELIOT) in Pregnant Women with Breast Cancer: From in Vivo Dosimetry to Clinical Practice. Breast Care (Basel) 2017; 12:396-400. [PMID: 29456472 PMCID: PMC5803713 DOI: 10.1159/000479862] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND The aim of this study was to confirm our preliminary results with in vivo dosimetry in non-pregnant breast cancer patients receiving electron beam intraoperative radiotherapy (ELIOT) and to report on the first treatment in a pregnant woman. PATIENTS AND METHODS Following our previous experience, 5 non-pregnant patients receiving ELIOT to the tumor bed after breast-conserving surgery (BCS) were studied with thermoluminescent dosimeters positioned in the subdiaphragmatic region, within the uterus, and in the ovarian region. In December 2011, the first pregnant breast cancer patient underwent BCS and ELIOT (21 Gy at 90% isodose) during the 15th week of gestation. RESULTS The mean dose to the subdiaphragmatic external region in the 5 non-pregnant patients was 5.57 mGy, while pelvic measurements were below 1 mGy. The actual dosimetry of the pregnant patient showed a mean subdiaphragmatic dose of 4.34 mGy, a mean suprapubic dose of 1.64 mGy, and mean ovarian doses of 1.48 mGy (right-sided) and 1.44 mGy (left-sided). The expected dose to the fetus was estimated as 0.84 mGy (0.004% of the prescribed dose). CONCLUSION ELIOT as an anticipated boost to the breast could be considered in pregnant women in the early second trimester, postponing whole-breast irradiation after delivery.
Collapse
Affiliation(s)
- Maria Leonardi
- Advanced Radiotherapy Center, European Institute of Oncology, Milan, Italy
| | - Agnese Cecconi
- Scientific Direction, European Institute of Oncology, Milan, Italy
- University of Milan, Milan, Italy
| | - Rosa Luraschi
- Unit of Medical Physics, European Institute of Oncology, Milan, Italy
| | - Elena Rondi
- Unit of Medical Physics, European Institute of Oncology, Milan, Italy
| | - Federica Cattani
- Unit of Medical Physics, European Institute of Oncology, Milan, Italy
| | - Roberta Lazzari
- Advanced Radiotherapy Center, European Institute of Oncology, Milan, Italy
| | - Anna Morra
- Advanced Radiotherapy Center, European Institute of Oncology, Milan, Italy
| | - Santos Soto
- Medica Sur Hospital Breast Center, Mexico City, Mexico
| | - Vanna Zanagnolo
- Gynecologic Cancer Surgery, European Institute of Oncology, Milan, Italy
| | | | - Oreste Gentilini
- Breast Cancer Surgery, European Institute of Oncology, Milan, Italy
- Current address: Breast Surgery Unit, San Raffaele University Hospital, Milan, Italy
| | - Fedro Peccatori
- Fertility and Procreation Unit, European Institute of Oncology, Milan, Italy
| | - Barbara Jereczek-Fossa
- Advanced Radiotherapy Center, European Institute of Oncology, Milan, Italy
- University of Milan, Milan, Italy
| | - Roberto Orecchia
- Scientific Direction, European Institute of Oncology, Milan, Italy
- University of Milan, Milan, Italy
- National Center of Oncology Hadrontherapy (CNAO foundation), Pavia, Italy
| |
Collapse
|
16
|
Mazonakis M, Damilakis J. Estimation and reduction of the radiation dose to the fetus from external-beam radiotherapy. Phys Med 2017; 43:148-152. [DOI: 10.1016/j.ejmp.2017.09.130] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Revised: 07/18/2017] [Accepted: 09/17/2017] [Indexed: 01/18/2023] Open
|
17
|
Kry SF, Bednarz B, Howell RM, Dauer L, Followill D, Klein E, Paganetti H, Wang B, Wuu CS, George Xu X. AAPM TG 158: Measurement and calculation of doses outside the treated volume from external-beam radiation therapy. Med Phys 2017; 44:e391-e429. [DOI: 10.1002/mp.12462] [Citation(s) in RCA: 164] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Revised: 05/17/2017] [Accepted: 05/25/2017] [Indexed: 12/14/2022] Open
Affiliation(s)
- Stephen F. Kry
- Department of Radiation Physics; MD Anderson Cancer Center; Houston TX 77054 USA
| | - Bryan Bednarz
- Department of Medical Physics; University of Wisconsin; Madison WI 53705 USA
| | - Rebecca M. Howell
- Department of Radiation Physics; MD Anderson Cancer Center; Houston TX 77054 USA
| | - Larry Dauer
- Departments of Medical Physics/Radiology; Memorial Sloan-Kettering Cancer Center; New York NY 10065 USA
| | - David Followill
- Department of Radiation Physics; MD Anderson Cancer Center; Houston TX 77054 USA
| | - Eric Klein
- Department of Radiation Oncology; Washington University; Saint Louis MO 63110 USA
| | - Harald Paganetti
- Department of Radiation Oncology; Massachusetts General Hospital and Harvard Medical School; Boston MA 02114 USA
| | - Brian Wang
- Department of Radiation Oncology; University of Louisville; Louisville KY 40202 USA
| | - Cheng-Shie Wuu
- Department of Radiation Oncology; Columbia University; New York NY 10032 USA
| | - X. George Xu
- Department of Mechanical, Aerospace, and Nuclear Engineering; Rensselaer Polytechnic Institute; Troy NY 12180 USA
| |
Collapse
|
18
|
Owrangi AM, Roberts DA, Covington EL, Hayman JA, Masi KM, Lee C, Moran JM, Prisciandaro JI. Revisiting fetal dose during radiation therapy: evaluating treatment techniques and a custom shield. J Appl Clin Med Phys 2016; 17:34-46. [PMID: 27685109 PMCID: PMC5874082 DOI: 10.1120/jacmp.v17i5.6135] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Revised: 03/31/2016] [Accepted: 03/28/2016] [Indexed: 11/23/2022] Open
Abstract
To create a comprehensive dataset of peripheral dose (PD) measurements from a new generation of linear accelerators with and without the presence of a newly designed fetal shield, PD measurements were performed to evaluate the effects of depth, field size, distance from the field edge, collimator angle, and beam modi-fiers for common treatment protocols and modalities. A custom fetal lead shield was designed and made for our department that allows external beam treatments from multiple angles while minimizing the need to adjust the shield during patient treatments. PD measurements were acquired for a comprehensive series of static fields on a stack of Solid Water. Additionally, PDs from various clinically relevant treatment scenarios for pregnant patients were measured using an anthropomorphic phantom that was abutted to a stack of Solid Water. As expected, the PD decreased as the distance from the field edge increased and the field size decreased. On aver-age, a PD reduction was observed when a 90° collimator rotation was applied and/or when the tertiary MLCs and jaws defined the field aperture. However, the effect of the collimator rotation (90° versus 0°) in PD reduction was not found to be clini-cally significant when the tertiary MLCs were used to define the field aperture. In the presence of both the MLCs and the fetal shield, the PD was reduced by 58% at a distance of 10 cm from the field edge. The newly designed fetal shield may effectively reduce fetal dose and is relatively easy to setup. Due to its design, we are able to use a broad range of treatment techniques and beam angles. We believe the acquired comprehensive PD dataset collected with and without the fetal shield will be useful for treatment teams to estimate fetal dose and help guide decisions on treat-ment techniques without the need to perform pretreatment phantom measurements.
Collapse
|
19
|
Puvanesarajah V, Spiker AM, Shannon BA, Grundy M, Levin AS, Morris CD. Evaluation and management of the pregnant patient with suspected primary musculoskeletal tumor or metastatic carcinoma to bone. Surg Oncol 2016; 25:212-22. [PMID: 27566025 DOI: 10.1016/j.suronc.2016.05.024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Accepted: 05/20/2016] [Indexed: 01/26/2023]
Abstract
Primary musculoskeletal cancer and metastatic disease to bone in pregnant patients presents major treatment challenges. Although uncommon, musculoskeletal malignancies in pregnant women have been reported. When diagnosing and treating these patients, the mother's health must be managed appropriately while ensuring that fetal development is not deleteriously affected. Extensive radiographic imaging and more advanced techniques are often necessary to fully characterize the extent of disease. When possible, magnetic resonance imaging should be used instead of computed tomography to limit exposure of the conceptus to radiation. If treatment is needed, therapeutic radiation, chemotherapy, and surgery should be considered. Surgical resection is the foundation of treatment of early-stage primary bone tumors and soft-tissue sarcomas during pregnancy. With surgery, anesthesia and thromboprophylaxis are important considerations. If chemotherapy is required, administration should be avoided in the first trimester to limit harm to the fetus. Therapeutic radiation should similarly be avoided during the first trimester and often can be postponed until after delivery.
Collapse
Affiliation(s)
- Varun Puvanesarajah
- Department of Orthopaedic Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - Andrea M Spiker
- Department of Orthopaedic Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - Brett A Shannon
- Department of Orthopaedic Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - Maureen Grundy
- Division of Maternal Fetal Medicine, Department of Gynecology and Obstetrics, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - Adam S Levin
- Division of Orthopaedic Oncology, Department of Orthopaedic Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - Carol D Morris
- Division of Orthopaedic Oncology, Department of Orthopaedic Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA.
| |
Collapse
|
20
|
Frankl M, Macián-Juan R. Monte Carlo simulation of secondary radiation exposure from high-energy photon therapy using an anthropomorphic phantom. RADIATION PROTECTION DOSIMETRY 2016; 168:537-545. [PMID: 26311702 DOI: 10.1093/rpd/ncv381] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Accepted: 08/01/2015] [Indexed: 06/04/2023]
Abstract
The development of intensity-modulated radiotherapy treatments delivering large amounts of monitor units (MUs) recently raised concern about higher risks for secondary malignancies. In this study, optimised combinations of several variance reduction techniques (VRTs) have been implemented in order to achieve a high precision in Monte Carlo (MC) radiation transport simulations and the calculation of in- and out-of-field photon and neutron dose-equivalent distributions in an anthropomorphic phantom using MCNPX, v.2.7. The computer model included a Varian Clinac 2100C treatment head and a high-resolution head phantom. By means of the applied VRTs, a relative uncertainty for the photon dose-equivalent distribution of <1 % in-field and 15 % in average over the rest of the phantom could be obtained. Neutron dose equivalent, caused by photonuclear reactions in the linear accelerator components at photon energies of approximately >8 MeV, has been calculated. Relative uncertainty, calculated for each voxel, could be kept below 5 % in average over all voxels of the phantom. Thus, a very detailed neutron dose distribution could be obtained. The achieved precision now allows a far better estimation of both photon and especially neutron doses out-of-field, where neutrons can become the predominant component of secondary radiation.
Collapse
Affiliation(s)
- Matthias Frankl
- Department of Nuclear Engineering, Technische Universität München, Garching 85748, Germany
| | - Rafael Macián-Juan
- Department of Nuclear Engineering, Technische Universität München, Garching 85748, Germany
| |
Collapse
|
21
|
Geng C, Moteabbed M, Seco J, Gao Y, George Xu X, Ramos-Méndez J, Faddegon B, Paganetti H. Dose assessment for the fetus considering scattered and secondary radiation from photon and proton therapy when treating a brain tumor of the mother. Phys Med Biol 2015; 61:683-95. [DOI: 10.1088/0031-9155/61/2/683] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
22
|
Morris ZS, Weichert JP, Saker J, Armstrong EA, Besemer A, Bednarz B, Kimple RJ, Harari PM. Therapeutic combination of radiolabeled CLR1404 with external beam radiation in head and neck cancer model systems. Radiother Oncol 2015; 116:504-9. [PMID: 26123834 PMCID: PMC4609259 DOI: 10.1016/j.radonc.2015.06.015] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Revised: 06/10/2015] [Accepted: 06/13/2015] [Indexed: 01/29/2023]
Abstract
BACKGROUND AND PURPOSE CLR1404 is a phospholipid ether that exhibits selective uptake and retention in malignant tissues. Radiolabeled CLR1404 enables tumor-specific positron-emission tomography (PET) imaging ((124)I) and targeted delivery of ionizing radiation ((131)I). Here we describe the first preclinical studies of this diapeutic molecule in head and neck cancer (HNC) models. MATERIAL AND METHODS Tumor-selective distribution of (124)I-CLR1404 and therapeutic efficacy of (131)I-CLR1404 were tested in HNC cell lines and patient-derived xenograft tumor models. Monte Carlo dose calculations and (124)I-CLR1404 PET/CT imaging were used to examine (131)I-CLR1404 dosimetry in preclinical HNC tumor models. RESULTS HNC tumor xenograft studies including patient-derived xenografts demonstrate tumor-selective uptake and retention of (124)I-CLR1404 resulting in a model of highly conformal dose distribution for (131)I-CLR1404. We observe dose-dependent response to (131)I-CLR1404 with respect to HNC tumor xenograft growth inhibition and this effect is maintained together with external beam radiation. CONCLUSIONS We confirm the utility of CLR1404 for tumor imaging and treatment of HNC. This promising agent warrants further investigation in a developing phase I trial combining (131)I-CLR1404 with reduced-dose external beam radiation in patients with loco-regionally recurrent HNC.
Collapse
Affiliation(s)
- Zachary S Morris
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, United States
| | - Jamey P Weichert
- Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, United States
| | - Jarob Saker
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, United States
| | - Eric A Armstrong
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, United States
| | - Abigail Besemer
- Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, United States
| | - Bryan Bednarz
- Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, United States
| | - Randall J Kimple
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, United States
| | - Paul M Harari
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, United States.
| |
Collapse
|
23
|
Baugh CW, Liang LJ, Probst MA, Sun BC. National cost savings from observation unit management of syncope. Acad Emerg Med 2015. [PMID: 26204970 DOI: 10.1111/acem.12720] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
OBJECTIVES Syncope is a frequent emergency department (ED) presenting complaint and results in a disproportionate rate of hospitalization with variable management strategies. The objective was to estimate the annual national cost savings, reduction in inpatient hospitalizations, and reduction in hospital bed hours from implementation of protocolized care in an observation unit. METHODS We created a Monte Carlo simulation by building a model that reflects current clinical practice in the United States and uses inputs gathered from the most recent available peer-reviewed literature and national survey data. ED visit volume was adjusted to reflect observation unit availability and the portion of observation visits requiring subsequent inpatient care. A recent multicenter randomized controlled study informed the cost savings and length of stay reduction per observation unit visit model inputs. The study population included patients aged 50 years and older with syncope deemed at intermediate risk for serious 30-day cardiovascular outcomes. RESULTS The mean (±SD) annual cost savings was estimated to be $108 million (±$89 million) from avoiding 235,000 (±13,900) inpatient admissions, resulting in 4,297,000 (±1,242,000) fewer hospital bed hours. CONCLUSIONS The potential national cost savings for managing selected patients with syncope in a dedicated observation unit is substantial. Syncope is one of many conditions suitable for care in an observation unit as an alternative to an inpatient setting. As pressure to decrease hospital length of stay and bill short-stay hospitalizations as observation increases, syncope illustrates the value of observation unit care.
Collapse
Affiliation(s)
| | - Li-Jung Liang
- Division of General Internal Medicine and Health Services Research; David Geffen School of Medicine at UCLA; Los Angeles CA
| | - Marc A. Probst
- Department of Emergency Medicine; Ichan School of Medicine at Mount Sinai; New York NY
| | - Benjamin C. Sun
- Department of Emergency Medicine; Oregon Health & Science University; Portland OR
| |
Collapse
|
24
|
Lee C, Jung JW, Pelletier C, Pyakuryal A, Lamart S, Kim J, Lee C. Reconstruction of organ dose for external radiotherapy patients in retrospective epidemiologic studies. Phys Med Biol 2015; 60:2309-24. [PMID: 25715852 PMCID: PMC4422070 DOI: 10.1088/0031-9155/60/6/2309] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Organ dose estimation for retrospective epidemiological studies of late effects in radiotherapy patients involves two challenges: radiological images to represent patient anatomy are not usually available for patient cohorts who were treated years ago, and efficient dose reconstruction methods for large-scale patient cohorts are not well established. In the current study, we developed methods to reconstruct organ doses for radiotherapy patients by using a series of computational human phantoms coupled with a commercial treatment planning system (TPS) and a radiotherapy-dedicated Monte Carlo transport code, and performed illustrative dose calculations. First, we developed methods to convert the anatomy and organ contours of the pediatric and adult hybrid computational phantom series to Digital Imaging and Communications in Medicine (DICOM)-image and DICOM-structure files, respectively. The resulting DICOM files were imported to a commercial TPS for simulating radiotherapy and dose calculation for in-field organs. The conversion process was validated by comparing electron densities relative to water and organ volumes between the hybrid phantoms and the DICOM files imported in TPS, which showed agreements within 0.1 and 2%, respectively. Second, we developed a procedure to transfer DICOM-RT files generated from the TPS directly to a Monte Carlo transport code, x-ray Voxel Monte Carlo (XVMC) for more accurate dose calculations. Third, to illustrate the performance of the established methods, we simulated a whole brain treatment for the 10 year-old male phantom and a prostate treatment for the adult male phantom. Radiation doses to selected organs were calculated using the TPS and XVMC, and compared to each other. Organ average doses from the two methods matched within 7%, whereas maximum and minimum point doses differed up to 45%. The dosimetry methods and procedures established in this study will be useful for the reconstruction of organ dose to support retrospective epidemiological studies of late effects in radiotherapy patients.
Collapse
Affiliation(s)
- Choonik Lee
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
| | | | | | - Anil Pyakuryal
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Rockville, MD
| | - Stephanie Lamart
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Rockville, MD
| | - Jongoh Kim
- Radiation Oncology, University of Pittsburg Cancer Institute
| | - Choonsik Lee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Rockville, MD
| |
Collapse
|
25
|
Amant F, Han SN, Gziri MM, Vandenbroucke T, Verheecke M, Van Calsteren K. Management of cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol 2015; 29:741-53. [PMID: 25797199 DOI: 10.1016/j.bpobgyn.2015.02.006] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Revised: 02/18/2015] [Accepted: 02/23/2015] [Indexed: 12/20/2022]
Abstract
A multidisciplinary discussion is necessary to tackle a complex and infrequent medical problem such as cancer occurring during pregnancy. Pregnancy does not predispose to cancer, but cancers occurring in women of reproductive age are encountered during pregnancy. Ultrasonography and magnetic resonance imaging are the preferred staging examinations, but also a sentinel node staging procedure is possible during pregnancy. Standard cancer treatment is aimed for. Operations can safely be performed during pregnancy, but surgery of genital cancers can be challenging. The observation that chemotherapy administered during the second or third trimester of pregnancy, that is, after the period of organogenesis, has little effect on the long-term outcome of children adds to the therapeutic armamentarium during pregnancy. Cancer treatment during pregnancy adds in the continuation of the pregnancy and the prevention of prematurity.
Collapse
Affiliation(s)
- Frédéric Amant
- Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium.
| | - Sileny N Han
- Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium
| | - Mina Mhallem Gziri
- Department of Obstetrics and Gynecology, Cliniques Universitaires St Luc, UCL, Brussels, Belgium
| | - Tineke Vandenbroucke
- Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium
| | - Magali Verheecke
- Gynecological Oncology, Department of Obstetrics and Gynecology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium
| | - Kristel Van Calsteren
- Department of Obstetrics and Gynecology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| |
Collapse
|
26
|
Taddei PJ, Jalbout W, Howell RM, Khater N, Geara F, Homann K, Newhauser WD. Analytical model for out-of-field dose in photon craniospinal irradiation. Phys Med Biol 2013; 58:7463-79. [PMID: 24099782 DOI: 10.1088/0031-9155/58/21/7463] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The prediction of late effects after radiotherapy in organs outside a treatment field requires accurate estimations of out-of-field dose. However, out-of-field dose is not calculated accurately by commercial treatment planning systems (TPSs). The purpose of this study was to develop and test an analytical model for out-of-field dose during craniospinal irradiation (CSI) from photon beams produced by a linear accelerator. In two separate evaluations of the model, we measured absorbed dose for a 6 MV CSI using thermoluminescent dosimeters placed throughout an anthropomorphic phantom and fit the measured data to an analytical model of absorbed dose versus distance outside of the composite field edge. These measurements were performed in two separate clinics-the University of Texas MD Anderson Cancer Center (MD Anderson) and the American University of Beirut Medical Center (AUBMC)-using the same phantom but different linear accelerators and TPSs commissioned for patient treatments. The measurement at AUBMC also included in-field locations. Measured dose values were compared to those predicted by TPSs and parameters were fit to the model in each setting. In each clinic, 95% of the measured data were contained within a factor of 0.2 and one root mean square deviation of the model-based values. The root mean square deviations of the mathematical model were 0.91 cGy Gy(-1) and 1.67 cGy Gy(-1) in the MD Anderson and AUBMC clinics, respectively. The TPS predictions agreed poorly with measurements in regions of sharp dose gradient, e.g., near the field edge. At distances greater than 1 cm from the field edge, the TPS underestimated the dose by an average of 14% ± 24% and 44% ± 19% in the MD Anderson and AUBMC clinics, respectively. The in-field measured dose values of the measurement at AUBMC matched the dose values calculated by the TPS to within 2%. Dose algorithms in TPSs systematically underestimated the actual out-of-field dose. Therefore, it is important to use an improved model based on measurements when estimating out-of-field dose. The model proposed in this study performed well for this purpose in two clinics and may be applicable in other clinics with similar treatment field configurations.
Collapse
Affiliation(s)
- Phillip J Taddei
- Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Graduate School of Biomedical Sciences, The University of Texas at Houston, Houston, TX 77030, USA. Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon
| | | | | | | | | | | | | |
Collapse
|
27
|
Assaidi A, Sbragia P, Fraisse A. Transcatheter therapy for aortic coarctation with severe systemic hypertension during pregnancy. Catheter Cardiovasc Interv 2013; 82:556-9. [PMID: 22511530 DOI: 10.1002/ccd.24404] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2012] [Revised: 02/28/2012] [Accepted: 03/03/2012] [Indexed: 11/12/2022]
Abstract
Aortic coarctation is an unusual cause of hypertension during pregnancy and its management is not clarified. We report transcatheter balloon dilatation and stenting for native aortic coarctation in a 22-year-old pregnant woman with severe and uncontrolled systemic hypertension. Arterial blood pressure could be successfully controlled with medical treatment during the rest of the pregnancy and the patient underwent uneventful delivery. No adverse events or recoarctation was observed during 24 months clinical follow-up. In conclusion, native aortic coarctation can be successfully treated during pregnancy with transcatheter therapy. More experience is needed to confirm the safety and efficacy of such management.
Collapse
Affiliation(s)
- Anass Assaidi
- Cardiologie Pédiatrique, Hôpital de la Timone-Enfants, 13385, Marseille Cedex 05, France
| | | | | |
Collapse
|
28
|
Atarod M, Shokrani P. Monte Carlo Study of Fetal Dosimetry Parameters for 6 MV Photon Beam. JOURNAL OF MEDICAL SIGNALS & SENSORS 2013; 3:31-6. [PMID: 24083135 PMCID: PMC3785068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2012] [Accepted: 01/14/2013] [Indexed: 10/26/2022]
Abstract
Because of the adverse effects of ionizing radiation on fetuses, prior to radiotherapy of pregnant patients, fetal dose should be estimated. Fetal dose has been studied by several authors in different depths in phantoms with various abdomen thicknesses (ATs). In this study, the effect of maternal AT and depth in fetal dosimetry was investigated, using peripheral dose (PD) distribution evaluations. A BEAMnrc model of Oncor linac using out of beam components was used for dose calculations in out of field border. A 6 MV photon beam was used to irradiate a chest phantom. Measurements were done using EBT2 radiochromic film in a RW3 phantom as abdomen. The followings were measured for different ATs: Depth PD profiles at two distances from the field's edge, and in-plane PD profiles at two depths. The results of this study show that PD is depth dependent near the field's edge. The increase in AT does not change PD depth of maximum and its distribution as a function of distance from the field's edge. It is concluded that estimating the maximum fetal dose, using a flat phantom, i.e., without taking into account the AT, is possible. Furthermore, an in-plane profile measured at any depth can represent the dose variation as a function of distance. However, in order to estimate the maximum PD the depth of D max in out of field should be used for in-plane profile measurement.
Collapse
Affiliation(s)
- Maryam Atarod
- Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Parvaneh Shokrani
- Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
29
|
Baugh CW, Venkatesh AK, Hilton JA, Samuel PA, Schuur JD, Bohan JS. Making greater use of dedicated hospital observation units for many short-stay patients could save $3.1 billion a year. Health Aff (Millwood) 2012; 31:2314-23. [PMID: 23019185 DOI: 10.1377/hlthaff.2011.0926] [Citation(s) in RCA: 102] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Using observation units in hospitals to provide care to certain patients can be more efficient than admitting them to the hospital and can result in shorter lengths-of-stay and lower costs. However, such units are present in only about one-third of US hospitals. We estimated national cost savings that would result from increasing the prevalence and use of observation units for patients whose stay there would be shorter than twenty-four hours. Using a systematic literature review, national survey data, and a simulation model, we estimated that if hospitals without observation units had them in place, the average cost savings per patient would be $1,572, annual hospital savings would be $4.6 million, and national cost savings would be $3.1 billion. Future policies intended to increase the cost-efficiency of hospital care should include support for observation unit care as an alternative to short-stay inpatient admission.
Collapse
|
30
|
Garny S, Rühm W, Zankl M, Wagner FM, Paretzke HG. First steps towards a fast-neutron therapy planning program. Radiat Oncol 2011; 6:163. [PMID: 22118299 PMCID: PMC3261826 DOI: 10.1186/1748-717x-6-163] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Accepted: 11/25/2011] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The Monte Carlo code GEANT4 was used to implement first steps towards a treatment planning program for fast-neutron therapy at the FRM II research reactor in Garching, Germany. Depth dose curves were calculated inside a water phantom using measured primary neutron and simulated primary photon spectra and compared with depth dose curves measured earlier. The calculations were performed with GEANT4 in two different ways, simulating a simple box geometry and splitting this box into millions of small voxels (this was done to validate the voxelisation procedure that was also used to voxelise the human body). RESULTS In both cases, the dose distributions were very similar to those measured in the water phantom, up to a depth of 30 cm. In order to model the situation of patients treated at the FRM II MEDAPP therapy beamline for salivary gland tumors, a human voxel phantom was implemented in GEANT4 and irradiated with the implemented MEDAPP neutron and photon spectra. The 3D dose distribution calculated inside the head of the phantom was similar to the depth dose curves in the water phantom, with some differences that are explained by differences in elementary composition. The lateral dose distribution was studied at various depths. The calculated cumulative dose volume histograms for the voxel phantom show the exposure of organs at risk surrounding the tumor. CONCLUSIONS In order to minimize the dose to healthy tissue, a conformal treatment is necessary. This can only be accomplished with the help of an advanced treatment planning system like the one developed here. Although all calculations were done for absorbed dose only, any biological dose weighting can be implemented easily, to take into account the increased radiobiological effectiveness of neutrons compared to photons.
Collapse
Affiliation(s)
- Sylvia Garny
- Helmholtz Zentrum München, Institut für Strahlenschutz, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
| | | | | | | | | |
Collapse
|
31
|
Mazonakis M, Tzedakis A, Varveris C, Damilakis J. Radiotherapy for supradiaphragmatic Hodgkin’s disease: Determination of the proper fetal shielding conditions using Monte Carlo methodology. Phys Med 2011; 27:181-7. [DOI: 10.1016/j.ejmp.2010.12.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2010] [Revised: 12/10/2010] [Accepted: 12/14/2010] [Indexed: 10/18/2022] Open
|
32
|
Han Z, Ng SK, Bhagwat MS, Lyatskaya Y, Zygmanski P. Evaluation of MatriXX for IMRT and VMAT dose verifications in peripheral dose regions. Med Phys 2010; 37:3704-14. [PMID: 20831078 DOI: 10.1118/1.3455707] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE MatriXX is a two-dimensional ion chamber array designed for IMRT/VMAT (RapidArc, IMAT, etc.) dose verifications. Its dosimetric properties have been characterized for megavoltage beams in a number of studies; however, to the best of the authors' knowledge, there is still a lack of an investigation into its performance in the peripheral or low dose regions. In this work, the authors have carried out a systematic study on this issue. METHODS The authors compare the performance of MatriXX with a cylindrical ion chamber in solid water phantoms in the peripheral dose regions. The comparisons are performed for a number of typical irradiation conditions that involve different gantry and/or MLC motions, field sizes, and distances to the target including static gantry/open fields, static gantry/sweeping MLC gap (mimicking an IMRT delivery), dynamic gantry/oscillating sweeping MLC gap (mimicking a VMAT delivery), as well as clinical IMRT and VMAT plans. RESULTS MatriXX, when used according to the manufacturer's recommendations, is found to disagree with an ion chamber in peripheral dose regions. This disagreement has been attributed to four types of MatriXX errors, namely, positive bias, over-response to scattered doses, round-off error, and angular dependence, all of which contribute to dose inaccuracies in the peripheral regions. The positive bias, which is independent of the dose level, is cumulative when MatriXX operates in the movie mode. The accumulation is proportional to the number of movie frames (snaps) when the sampling time is greater than 500 ms and is proportional to the overall movie time for a sampling time shorter than 500 ms. This behavior suggests multiple sources of the bias. MatriXX is also found to over-respond to peripheral doses by about 2.0% for the regions investigated in this work (3-15 cm from the field edge), where phantom scatter and collimator scatter dominate. Round-off error is determined to be due to insufficient precision in conversion of the raw signals to MatriXX software data for low doses. Angular dependence is defined as the dose response of MatriXX at different gantry angles. Up to 8% difference in detector response has been observed between 0 degree and 180 degrees. Possible sources of these errors are discussed and a correction method is suggested. With corrections, MatriXX shows good agreement with the ion chamber in all cases involving different gantry and/or MLC dynamics, as well as the clinical plans. For both primary and peripheral doses, MatriXX shows dose linearity down to 2 cGy with an accuracy of within 1% of the local dose. CONCLUSIONS The performance of MatriXX has been systematically evaluated in the peripheral dose regions. Major sources of error associated with MatriXX are identified and a correction method is suggested. This method has been successfully tested using both experimental and clinical plans. In all cases, good agreements between MatriXX and an ion chamber are achieved after corrections. The authors conclude that with proper corrections, MatriXX can be reliably used for peripheral dose measurements within the ranges studied.
Collapse
Affiliation(s)
- Zhaohui Han
- Department of Radiation Oncology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
| | | | | | | | | |
Collapse
|
33
|
Estimation of organs doses and radiation-induced secondary cancer risk from scattered photons for conventional radiation therapy of nasopharynx: a Monte Carlo study. Jpn J Radiol 2010; 28:398-403. [PMID: 20585932 DOI: 10.1007/s11604-010-0432-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2009] [Accepted: 02/26/2010] [Indexed: 10/19/2022]
Abstract
PURPOSE We used Monte Carlo modeling to calculate the organs doses due to out-of field photons during radiation therapy of the nasopharynx. MATERIALS AND METHODS A medical internal radiation dose (MIRD)-based mathematical phantom resembling an adult man was modeled by MCNP4C MC code. Three validated models of a cobalt-60 machine, a 6-MV photon beam of a Varian 2300 C/D linac, and a 9-MV photon beam of a Neptun linac were used to simulate the isocentric irradiation of a mathematical phantom with two lateral fields of the nasopharynx. The organspecific dose, effective dose, and cancer risk estimates were obtained. RESULTS The effective doses for out-of-field radiation were 320, 295, and 248 mSv for the (60)Co beam, 6-MV beam, and 9-MV beam devices, respectively, for a 70-Gy tumor dose. The fatal cancer risks of 1.6%, 1.5%, and 1.2% were estimated for a 70-Gy tumor dose of (60)Co and the 6- and 9-MV photon beams, respectively. CONCLUSION Our results regarding the effective dose and cancer risk are in agreement with previously published experimental results on conventional radiation therapy. Further investigation on patients' out-of-field dose to provide more knowledge on various radiotherapy techniques is suggested.
Collapse
|
34
|
Han B, Bednarz B, Xu XG. A study of the shielding used to reduce leakage and scattered radiation to the fetus in a pregnant patient treated with a 6-MV external X-ray beam. HEALTH PHYSICS 2009; 97:581-589. [PMID: 19901592 PMCID: PMC3376892 DOI: 10.1097/01.hp.0000363838.70546.4c] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A Monte Carlo-based procedure has been developed to assess the shielded fetal doses from 6 MV external photon beam radiation treatments and improve upon existing techniques that are based on AAPM Task Group Report 36 (TG-36). Anatomically realistic models of the pregnant patient representing 3- and 6-mo gestational stages were implemented into the MCNPX code together with a detailed accelerator model that is capable of simulating scattered and leakage radiation from the accelerator head. The phantom was shielded using suggested lead and Cerrobend in different locations and with different thicknesses. Absorbed doses to the fetus both with and without shielding were calculated considering typical mantle, head and neck, and brain treatment plans. The unshielded fetal doses tended to increase with decreasing distance from the field edge to the nearest fetal point and increasing of the field size. The unshielded absorbed doses to the fetus for all treatment plans ranged from a maximum of 4.08 microGy/MU (monitor unit) to a minimum 0.09 microGy/MU. The use of lead or Cerrobend shielding reduced the fetal doses by factors of up to 4. For an optimal shield half-value layer, the dose reduction between lead and Cerrobend was statistically insignificant. The maximum permitted MUs for the mantle treatments with shielding were calculated based on 5 cGy dose limits suggested by TG-36. The study demonstrates an accurate assessing tool that can be used to determine the absorbed dose to the fetus and to design the shielding as part of the treatment planning and risk management.
Collapse
Affiliation(s)
- Bin Han
- Nuclear Engineering and Engineering Physics, Rensselaer Polytechnic Institute, Troy, NY 12180
| | - Bryan Bednarz
- Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
| | - X. George Xu
- Nuclear Engineering and Engineering Physics, Rensselaer Polytechnic Institute, Troy, NY 12180
| |
Collapse
|
35
|
Bednarz B, Xu XG. Monte Carlo modeling of a 6 and 18 MV Varian Clinac medical accelerator for in-field and out-of-field dose calculations: development and validation. Phys Med Biol 2009; 54:N43-57. [PMID: 19141879 PMCID: PMC3376900 DOI: 10.1088/0031-9155/54/4/n01] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
There is a serious and growing concern about the increased risk of radiation-induced second cancers and late tissue injuries associated with radiation treatment. To better understand and to more accurately quantify non-target organ doses due to scatter and leakage radiation from medical accelerators, a detailed Monte Carlo model of the medical linear accelerator is needed. This paper describes the development and validation of a detailed accelerator model of the Varian Clinac operating at 6 and 18 MV beam energies. Over 100 accelerator components have been defined and integrated using the Monte Carlo code MCNPX. A series of in-field and out-of-field dose validation studies were performed. In-field dose distributions calculated using the accelerator models were tuned to match measurement data that are considered the de facto 'gold standard' for the Varian Clinac accelerator provided by the manufacturer. Field sizes of 4 cm x 4 cm, 10 cm x 10 cm, 20 cm x 20 cm and 40 cm x 40 cm were considered. The local difference between calculated and measured dose on the percent depth dose curve was less than 2% for all locations. The local difference between calculated and measured dose on the dose profile curve was less than 2% in the plateau region and less than 2 mm in the penumbra region for all locations. Out-of-field dose profiles were calculated and compared to measurement data for both beam energies for field sizes of 4 cm x 4 cm, 10 cm x 10 cm and 20 cm x 20 cm. For all field sizes considered in this study, the average local difference between calculated and measured dose for the 6 and 18 MV beams was 14 and 16%, respectively. In addition, a method for determining neutron contamination in the 18 MV operating model was validated by comparing calculated in-air neutron fluence with reported calculations and measurements. The average difference between calculated and measured neutron fluence was 20%. As one of the most detailed accelerator models for both in-field and out-of-field dose calculations, the model will be combined with anatomically realistic computational patient phantoms into a computational framework to calculate non-target organ doses to patients from various radiation treatment plans.
Collapse
Affiliation(s)
- Bryan Bednarz
- Nuclear Engineering and Engineering Physics, Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| | - X George Xu
- Nuclear Engineering and Engineering Physics, Rensselaer Polytechnic Institute, Troy, New York 12180, USA
| |
Collapse
|
36
|
Xu XG, Bednarz B, Paganetti H. A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Phys Med Biol 2008; 53:R193-241. [PMID: 18540047 PMCID: PMC4009374 DOI: 10.1088/0031-9155/53/13/r01] [Citation(s) in RCA: 293] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
It has been long known that patients treated with ionizing radiation carry a risk of developing a second cancer in their lifetimes. Factors contributing to the recently renewed concern about the second cancer include improved cancer survival rate, younger patient population as well as emerging treatment modalities such as intensity-modulated radiation treatment (IMRT) and proton therapy that can potentially elevate secondary exposures to healthy tissues distant from the target volume. In the past 30 years, external-beam treatment technologies have evolved significantly, and a large amount of data exist but appear to be difficult to comprehend and compare. This review article aims to provide readers with an understanding of the principles and methods related to scattered doses in radiation therapy by summarizing a large collection of dosimetry and clinical studies. Basic concepts and terminology are introduced at the beginning. That is followed by a comprehensive review of dosimetry studies for external-beam treatment modalities including classical radiation therapy, 3D-conformal x-ray therapy, intensity-modulated x-ray therapy (IMRT and tomotherapy) and proton therapy. Selected clinical data on second cancer induction among radiotherapy patients are also covered. Problems in past studies and controversial issues are discussed. The needs for future studies are presented at the end.
Collapse
Affiliation(s)
- X George Xu
- Nuclear Engineering and Engineering Physics, Rensselaer Polytechnic Institute, Troy, NY 12180, USA
| | | | | |
Collapse
|